XML 68 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMITMENTS AND CONTINGENCIES (Details Narrative)
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 08, 2017
USD ($)
Jul. 06, 2017
USD ($)
Mar. 19, 2018
CAD ($)
May 31, 2017
USD ($)
Oct. 25, 2016
USD ($)
Jun. 30, 2016
USD ($)
May 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Jan. 31, 2015
USD ($)
Sep. 30, 2014
USD ($)
Mar. 31, 2018
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2017
USD ($)
Mar. 31, 2018
CAD ($)
shares
Jun. 21, 2016
USD ($)
Operating lease periodic payment                 $ 709            
Frequency of periodic payment                 Monthly            
Operating lease rental expense                     $ 2,126 $ 2,126      
Operating lease expiration date                 May 31, 2017            
Lease agreement description                

The Company has negotiated and entered into a two-year amendment to that lease that commenced as of June 1, 2017 through May 31, 2019. The monthly rate from June 1, 2017 through May 31, 2018 is $709 per month and increases to $730 per month from June 1, 2018 through May 31, 2019.

            
SkyPharm [Member]                              
Operating lease periodic payment       $ 1,250           $ 4,802          
Frequency of periodic payment       Monthly           Monthly          
Term of operating lease                   6 years          
SkyPharm [Member] | Additional space [Member]                              
Operating lease periodic payment           $ 2,021 $ 886                
Frequency of periodic payment           Monthly Monthly                
SkyPharm [Member] | First Floor [Member]                              
Operating lease periodic payment               $ 886              
Frequency of periodic payment               Monthly              
CC Pharma GmbH [Member]                              
Non-refundable fee                             $ 454,800
Expense paid   $ 454,800                     $ 454,800    
Amplerissimo [Member]                              
Operating lease periodic payment                     $ 124        
Frequency of periodic payment                     Monthly        
Operating lease rental expense                     $ 406 352      
Operating lease renewal date                     Jul. 31, 2018        
Private Placement [Member]                              
Commitments and contingencies description

(1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering

                            
Lease agreement description

In connection with the Company’s November 16, 2017 Note offering, the Agent received a cash commission of $240,000, equal to eight (8%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase eight (8%) percent of the shares of Common Stock issued or issuable in the offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors, or 53,600 shares); however, will receive eight (8%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The Warrants are exercisable six (6) months after the date of issuance, or May 16, 2018.

                            
Agent commission recevied $ 240,000                            
Marathon Global Inc. [Member]                              
Description of equity acquisition agreement    

The Agreement is to remain in effect indefinitely unless Marathon fails to provide Market Competitive (as defined) product pricing and Marathon has not become profitable within five (5) years of this Agreement. Following a thirty (30) day due diligence period, and subject to satisfactory due diligence of the Company, Marathon shall: (a) grant the Company a 33 1/3% equity interest in Marathon as partial consideration for the Company’s distribution services; and (b) make a cash payment of CAD $2,000,000 to the Company, subject to repayment by the Company in Common Shares of the Company if it fails to meet certain performance milestones.

                        
Decahedron [Member]                              
Operating lease periodic payment         $ 2,470                    
Operating lease rental expense                     $ 11,800 4,729      
Operating lease expiration date         Oct. 24, 2021                    
MediHelm S.A. [Member] | SkyPharm [Member]                              
Operating lease periodic payment                       $ 8,758      
Frequency of periodic payment                       Monthly      
Operating lease rental expense                     33,180 $ 24,891      
Distribution and Equity Agreement [Member] | Marathon Global Inc. [Member]                              
Amount receivable upon satisfactory due diligence     $ 2,000,000                     $ 2,000,000  
Description for the additional consideration receivable under agreement    

The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. The Company was also given the right to nominate one director to the Marathon Board of Directors.

                        
Distribution and Equity Agreement [Member] | Marathon Global Inc. [Member] | Target 2 [Member]                              
Additional consideration receivable upon meeting of target     $ 2,750,000                        
Gross sales target for consideration receivable     13,000,000                        
Distribution and Equity Agreement [Member] | Marathon Global Inc. [Member] | Target 1 [Member]                              
Additional consideration receivable upon meeting of target     2,750,000                        
Gross sales target for consideration receivable     $ 6,500,000                        
Intellectual property sale agreement [Member] | Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member]                              
Operating lease periodic payment                     $ 1,500        
Common stock shares reserved | shares                           200,000  
Intellectual property sale agreement [Member] | Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Preclinical Trials [Member] | On October 1, 2016 [Member]                              
Common stock shares reserved | shares                           50,000  
Intellectual property sale agreement [Member] | Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | conclusion of Phase I testing [Member] | On October 1, 2016 [Member]                              
Common stock shares reserved | shares                           50,000  
Intellectual property sale agreement [Member] | Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Phase II testing [Member] | On October 1, 2016 [Member]                              
Common stock shares reserved | shares                           50,000  
Intellectual property sale agreement [Member] | Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Phase III testing [Member] | On October 1, 2016 [Member]                              
Common stock shares reserved | shares                           50,000